Search
Pafuramidine
go.drugbank.com/drugs/DB06532InvestigationalPafuramidine, a prodrug of furamidine, currently has orphan status for _Pneumocystis jiroveci_ pneumonia.
Celgosivir
go.drugbank.com/drugs/DB06580InvestigationalSynonyms: 6-O-ButanoylcastanospermineCategories: Heterocyclic Compounds, 2-RingTafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigationalTafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. … [A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsBosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigationalBosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive … Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrileFlupirtine
go.drugbank.com/drugs/DB06623InvestigationalFlupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe.
Categories: Heterocyclic Compounds, 1-RingIsavuconazonium
go.drugbank.com/drugs/DB06636ApprovedInvestigationalIsavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis … Isovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2B6 InducersProducts: CRESEMBA ® CAPSULAS, CRESEMBA® 200 MG POLVO LIOFILIZADO ESTERIL PARA RECONSTITUIRSafinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalSafinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Cytochrome P-450 Substrates, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesPasireotide
go.drugbank.com/drugs/DB06663ApprovedInvestigationalPasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSynonyms: cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)Esmirtazapine
go.drugbank.com/drugs/DB06678InvestigationalEsmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology. … This includes inverse agonist activity of H1 and 5-HT2 receptors and antagonism of α2-adrenergic receptors.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 3-RingSynonyms: (S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine